Meeting Coverage
In MS, Healthcare Inequities Based on Race & Ethnicity “Still Prevail”
Jun 22, 2023
In MS, Black and Hispanic patients had more trouble accessing care and reported lower-quality care...
Read MoreCurative-Intent Treatment Improves Survival in Early NSCLC Regardless of Race
Jun 21, 2023
Curative-intent therapy in patients with early non-small cell lung cancer resulted in “nearly...
Read MoreLiver Transplant Outcomes Worse for Black Patients With HCC
Jun 21, 2023
While liver transplantation was less likely for Black patients with HCC, those who did receive a...
Read MoreDemographics Impact Time to Treatment Initiation for Patients With HCC
Jun 21, 2023
Hepatocellular carcinoma (HCC) comprises 75% of all liver cancer diagnoses in the United...
Read MoreGreater Benefit of Adjuvant Chemo Noted in High-Risk Patients With eNSCLC
Jun 21, 2023
For early-stage non-small cell lung cancer (eNSCLC) surgical resection with possible adjuvant...
Read MoreProject Helps Improve Communication Between Clinicians & Patients With MS
Jun 20, 2023
“We saw a need to improve communication between patients and clinicians so that patients feel...
Read MoreKRAS Mutation Does Not Influence Atezolizumab Response in NSCLC
Jun 12, 2023
This retrospective analysis of the IMpower150 trial (NCT02486718) explored efficacy endpoints...
Read MoreAdding Pembrolizumab to Perioperative Chemotherapy Improves Event-Free Survival in Early-Stage NSCLC
Jun 12, 2023
In KEYNOTE-671, neoadjuvant pembrolizumab plus chemotherapy followed by surgery and adjuvant...
Read MoreWhat Can Real-World Evidence Teach Us About Atezolizumab Plus Bevacizumab in HCC?
Jun 8, 2023
Therapy with atezolizumab and bevacizumab improved recurrence-free survival in patients with...
Read MoreIMbrave050: Adjuvant Atezolizumab Plus Bevacizumab Provides Landmark Recurrence-Free Survival for HCC
Jun 8, 2023
Adjuvant therapy with atezolizumab and bevacizumab improved recurrence-free survival in patients...
Read MoreCortical Excitation/Inhibition Imbalance Has Predictive Value in MS
Jun 8, 2023
In MS, a lower cortical imbalance between excitation and inhibition may serve as a predictive...
Read MoreTwo Dietary Interventions Lead to Improvements in MS-Related Disability
Jun 7, 2023
It is recommended that neurologists discuss the benefits of improving diet quality with their...
Read MoreMeeting Coverage: ASCO Voices
Jun 1, 2023
ASCO Voices continues to be one of the most compelling sessions offered at the ASCO Annual...
Read MoreAncillary Educational Events
Jun 1, 2023
Ancillary events are functions held adjacent to the ASCO Annual Meeting, including, but not...
Read MoreCommunities of Practice
Jun 1, 2023
Connect with colleagues that share your passion and goals through one of ASCO’s new Communities of...
Read MoreEffects on Patient with HCC on Aspirin During In-Hospital Outcomes
May 25, 2023
Although new immunotherapies have been used, hepatocellular carcinoma (HCC) still presents a low...
Read MoreAnalyzing Adjuvant Atezo+Bev Vs. Active Surveillance in HCC Patients
May 25, 2023
In the IMbrave050 study, the combination of adjuvant atezo (atezolizumab) and bev (bevacizumab)...
Read More